iifl-logo

Marksans Pharma Ltd Dividend

Add as a Preferred Source on Google
322.4
(0.25%)
Sep 1, 2026|09:39:07 PM

Marksans Pharma CORPORATE ACTIONS

02/09/2025calendar-icon
02/09/2026calendar-icon
PurposeAnnouncement DateEx-DateRecord DateDividend AmountDividend per ShareRemark
Dividend26 May 202620 Aug 202620 Aug 20260.990Final
Further, kindly be informed that the Board has recommended a final dividend of Rs. 0.90 per Equity Share of face value of Re. 1/- per share (90%) for the financial year 2025-26. The dividend, if approved by the Members at the forthcoming Annual General Meeting (AGM) will be credited / dispatched within 30 days from the date of AGM. The Board of Directors of Marksans Pharma Limited fixed 20 August 2026 as the Record Date for payment of dividend. (As per BSE Announcement dated on: 03.07.2026)

Marksans Pharma: Related News

Marksans Pharma’s UK Subsidiary Relonchem Gets MHRA Approval for Moxonidine Tablets

In June, Relonchem also secured approval for oxybutynin hydrochloride oral solution, used in managing symptoms of an overactive bladder.

24 Sep 2025|09:58 AM
Read More
Marksans Pharma Secures EIR from USFDA for Subsidiary’s New York Facility

The inspection by the USFDA had taken place between April 16 and 24. After the visit, the company disclosed one observation under Form 483.

30 Jun 2025|05:57 PM
Read More
OrbiMed to Offload 2.27% Stake in Marksans Pharma via Block Deal

The block deal has been launched at a floor price of ₹249.95 per share, signaling a strategic partial exit by the investor.

11 Jun 2025|12:34 PM
Read More
Marksans Pharma’s Relonchem Gets UK MHRA Approval for Baclofen 10 mg

Relonchem Ltd has secured Marketing Authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Baclofen 10 mg Tablets

21 Mar 2025|12:02 PM
Read More
Marksans Pharma gets USFDA approval for anti-allergy drug

The US Food and Drug Administration (FDA) approved the pharmaceutical company's Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg.

22 Nov 2024|02:54 PM
Read More
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.